Journals / Nöropsikiyatri Arşivi / 2015 / Cilt: 52 - Sayı: 1

Siyaloreli Parkinson Hastalarında Tekrarlanan Botulinum Toksini Tedavisinin Etkileri

Effects of Repeated Botulinum Toxin Treatment for Sialorrhea in Patients with Parkinson's Disease

Pages
69–72
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further prospective clinical studies with larger number of patients and more longer duration of follow-up are needed to confirm our results

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: To evaluate the efficacy and adverse effects of repeated onabotulinumtoxinA (BoNT-A) treatment in patients suffering from Parkinson's disease (PD) with sialorrhea.Methods: A retrospective analysis of 16 patients with sialorrhea treated with BoNT-A at our movement disorders outpatient clinic was conducted from February 2009 to September 2013.
📊
Key Findings & Data:Results: The mean age of the patients was 70.00±9.82 years and the mean follow-up duration was 18.78±10.37 months.
💡
Conclusion & Impact:Further prospective clinical studies with larger number of patients and more longer duration of follow-up are needed to confirm our results
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: To evaluate the efficacy and adverse effects of repeated onabotulinumtoxinA (BoNT-A) treatment in patients suffering from Parkinson's disease (PD) with sialorrhea.Methods: A retrospective analysis of 16 patients with sialorrhea treated with BoNT-A at our movement disorders outpatient clinic was conducted from February 2009 to September 2013. A patient with adult cerebral palsy and a patient with PD who received only a single application were excluded. BoNT-A was injected into the parotid glands without ultrasound guidance. Pre-treatment sialorrhea severity was quantified according to the Drooling Frequency and Severity Scale (DFSS). The efficacy was evaluated four weeks after BoNT-A injections using DFSS and according to the subjective assessment of the patients and/or caregivers. Results: The mean age of the patients was 70.00±9.82 years and the mean follow-up duration was 18.78±10.37 months. Totally, 37 applications were performed. The mean BoNT-A total dose was 34.35±6.41 units. The mean scores of DFSS before and after injections were 7.00±1.03 and 3.21±0.89, respectively (p<0.001). Efficacy was 100%, and the mean experienced sialorrhea improvement was 71.78±12.95%. We found a significant difference between the first and last application in the mean duration of efficacy (17.28±9.21 weeks and 18.03±9.02 weeks, respectively, p=0.001). We did not observe side effects in this study group.Conclusion: Repeated injections of BoNT-A are safe and effective in treating sialorrhea in patients with PD. Based on our results, it seems that there is a maintenance of efficacy after a three-year period and an increase in the mean duration of efficacy with the number of injections. Further prospective clinical studies with larger number of patients and more longer duration of follow-up are needed to confirm our results

Özet

Amaç: Siyaloreli Parkinson hastalarında tekrarlanan onabotulinumtoxin A (BoNT-A) tedavisinin etkinlik ve yan etkilerini değerlendirmek.Yöntem: Hastanemiz hareket bozuklukları polikliniği'nde Şubat 2009'dan Eylül 2013'e kadar BoNT-A ile tedavi edilmiş olan siyaloreli 16 hastanın retrospektif analizi yapıldı. Erişkin serebral felçli bir hasta ve yalnızca bir uygulama yapılabilen bir Parkinson hastası dışlandı. BoNT-A, parotis bez-leri içine ultrason rehberliği olmadan enjekte edildi. Tedavi öncesi siyalo-re şiddeti Salya Sıklık ve Şiddet Ölçeği'ne (SSŞÖ) göre belirlendi. Etkinlik, BoNT-A enjeksiyonundan dört hafta sonra SSŞÖ ve hastalar ve/veya ba-kım verenlerin öznel değerlendirmesine göre ölçüldü.Bulgular: Hastaların yaş ortalaması 70,00±9,82 yıl, ortalama takip süresi 18,78±10,37 aydı. Toplam 37 uygulama yapıldı. Ortalama total BoNT-A dozu 34,35±6,41 üniteydi. Enjeksiyonlardan önceki ve sonraki ortalama SSŞÖ puanı sırayla 7,00±1,03 ve 3,21±0,89 idi (p<0,001). Etkinlik %100 ve deneyimlenen siyalore düzelmesi ortalaması %71,78±12,95 idi. İlk ve son uygulamalardaki ortalama etkinlik süresi arasında anlamlı fark bulundu (sırayla 17,28±9,21 hafta ve 18,03±9,02 hafta, p=0,001). Bu çalışma gru-bunda yan etki gözlenmedi.Sonuç: Parkinson hastalarında siyalore tedavisinde tekrarlanan BoNT-A enjeksiyonları güvenli ve etkindir. Sonuçlarımıza göre; üç yıl sonrasında etkinlik hala sürüyor ve enjeksiyon sayısı arttıkça ortalama etkinlik süresi uzuyor gibi görünmektedir. İleride yapılacak olan daha fazla hasta sayısı ve daha uzun takip süreli prospektif klinik çalışmalarla sonuçlarımızın doğru-lanması gerekmektedir.

🔖

Cite This Article

ŞEN, A., ARPACI, B. (2015). Siyaloreli Parkinson Hastalarında Tekrarlanan Botulinum Toksini Tedavisinin Etkileri. Nöropsikiyatri Arşivi, Cilt: 52 - Sayı: 1, 69–72. https://ajindex.com/articles/294398

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Kalf JG, Smit AM, Bloem BR, Zwarts MJ, Mulleners WM, Munneke M. Bot- ulinum toxin A for drooling in Parkinson's disease: a pilot study to compare submandibular to parotid gland injections. Parkinsonism Relat Disord 2007; 13:532-534. [CrossRef] Molloy L. Treatment of sialorrhoea in patients with Parkinson's disease: best current evidence. Curr Opin Neurol 2007; 20:493-498. [CrossRef] Jongerius PH, Joosten F, Hoogen FJ, Gabreels FJ, Rotteveel JJ. The treatment of drooling by ultrasoundguided intraglandular injections of botulinum toxin type A into the salivary glands. Laryngoscope 2003; 113:107-111. [CrossRef] Sochaiwskyj AE, Koheil RM, Bablich K, Milner M, Kenny DJ. Oral motor func- tioning, frequency of swallowing and drooling in normal children and in chil- dren with cerebral palsy. Arch Phys Med Rehabil 1986; 12:866-874.
  2. Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov Disord 2004; 19:137-141. [CrossRef] Stuchell RN, Mandel ID. Salivary gland dysfunction and swallowing disorders. Otolaryngol Clin North Am 1988; 21:649-661.
  3. Ellies M, Laskawi R, Gotz W, Arglebe C, Tormahlen G. Immunohistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat. Eur Arch Otorhinolaryngol 1999; 256:148- 152. [CrossRef] Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000; 54:244-247. [CrossRef] Jongerius PH, Rotteveel JJ, van Limbeek J, Gabreels FJ, van Hulst K, van den Hoogen FJ. Botulinum toxin effect on salivary flow rate in children with cere- bral palsy. Neurology 2004; 63:1371-1375. [CrossRef] Svetel M, Vasic M, Dragasevic N, Pekmezovic T, Petrovic I, Kostic V. Botulinum toxin in the treatment of sialorrhea. Vojnosanit Pregl 2009; 66:9-12. [CrossRef] Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka KV. Injections of botulinum toxin A into the salivary glands improve sialor- rhoea in amyotrophic lateral sclerosis. J Neurol Neurochir Psychiatry 2000; 69:121-123. [CrossRef] Breheret R, Bizon A, Jeufroy C, Laccourreye L. Ultrasound-guided botulinum toxin injections for treatment of drooling. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128:224-229. [CrossRef] Moller E, Karlsborg M, Bardow A, Lykkeaa J, Nissen FH, Bakke M. Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms. Acta Odontol Scand 2011; 69:151-157. [CrossRef] Thom